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Abstract: Systemic sclerosis (SSc) is an acquired multiorgan connective tissue disease with 
variable mortality and morbidity dictated by clinical subset type. The etiology of the basic disease 
and pathogenesis of the systemic autoimmunity, fibrosis, and fibroproliferative vasculopathy are 
unknown and debated. In this review, the spectrum of vascular abnormalities and the options 
currently available to treat the vascular manifestations of SSc are discussed. Also discussed is 
how the hallmark pathologies (ie, how autoimmunity, vasculopathy, and fibrosis of the disease) 
might be effected and interconnected with modulatory input from lysophospholipids, sphingosine 
1-phosphate, and lysophosphatidic acid.
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Introduction
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology with 
multiorgan involvement and a wide range of clinical manifestations. The incidence 
of SSc is about 20 cases per million population per year, and the prevalence is more 
than 250 patients per million population in the USA.1 Major organ involvement is 
associated with decreased survival in SSc. In one study, 9-year survival in SSc was 
about 39% when a major organ (skin, gastrointestinal [GI] tract, lung, kidney, and 
heart) is involved compared with 72% in case of mild or no organ involvement.2 The 
primary cause of death in SSc is now the lung. Pulmonary fibrosis and pulmonary 
hypertension (PH) cause more than half of all SSc-related deaths.1 The characteristic 
features of SSc include extensive fibrosis, fibroproliferative vasculopathy, systemic 
autoimmunity (autoantibodies and T cell autoantigen reactivity) and inflammation. 
There are two major forms of SSc: limited cutaneous (lcSSc) and diffuse cutaneous 
(dcSSc). These two forms differ mainly with regard to extent of skin involvement, 
autoantibody association, and the pattern of organ involvement (Table 1). In lcSSc, 
fibrosis of skin occurs on face and chest and distal elbows and knees, and it is associated 
with anticentromere antibody. Pulmonary hypertension is more common in lcSSc. In 
dcSSc, the skin involvement is more widespread, and it is associated with anti-DNA 
topoisomerase I (Scl-70) antibody. Pulmonary fibrosis and scleroderma renal crisis 
are more commonly associated with dcSSc. A third, less common form “SSc sine 
scleroderma” is also recognized, in which there is internal organ involvement with occa-
sional fibrosis of distal digits. Although SSc is considered a fibrosing disease, vascular 
involvement plays a major role in pathogenesis and organ dysfunction. SSc vascular 
disease involves vasculopathy with luminal occlusion, thrombosis, and vasospasm. Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Complex interactions between endothelial cells, vascular 
smooth muscle cells, extracellular matrix and circulating 
mediators contribute to vascular remodeling, vasospasm, 
and vessel occlusion. This article focuses primarily on the 
vascular aspects of SSc and how two lysophospholipids 
(sphingosine 1-phosphate [S1P] and lysophosphatidic acid 
[LPA]) recently shown to be elevated in SSc sera might 
assume roles in mediating vascular changes, autoimmunity, 
and fibrosis in the disease.
Mechanisms of SSc pathogenesis
Genetic associations
Current data indicate that SSc is a polygenic autoimmune 
disease with overlap of some susceptibility loci with other 
autoimmune diseases. Most notably, protein tyrosine 
phosphatase, nonreceptor type 22 (PTPN22) and signal 
transducers and activators of transcription-4 (STAT4) are 
associated not only with SSc but also with rheumatoid 
arthritis and systemic lupus erythematosus.3 Interferon 
regulating factor 5 (IRF5) and B cell scaffold protein 
with ankryn repeats (BANK1) polymorphisms have been 
associated with SSc.4 Several studies show some weak 
association of SSc with certain major histocompatibility 
complex (MHC) or human leukocyte antigen class II (human 
leukocyte antigen [HLA]-Class II) alleles;5 however, there 
are stronger HLA-Class II allelic associations with SSc-
specific autoantibodies. In a recent US study, DPB1*1301 
was most associated with antitopoisomerase 1 antibody (odds 
ratio 14), while anticentromere antibody was associated 
with DQB1*0501 and DQB1*26 epi alleles.5 Anti-RNA 
polymerase III was associated in Caucasian and Hispanic 
patients with DRB1*0404, DRB1*11, and DRB1*03 alleles 
and in African American patients with DRB1*08.5 It is 
unclear at present how these genetic associations relate to 
the pathogenesis of SSc. However, it is currently believed 
that a permissive genetic background coupled with an 
extraneous environmental trigger sets the disease in motion. 
Epidemiological and/or case reports have suggested SSc 
might be triggered by chronic occupational exposure to silica 
dust and organic solvents.6–8 Clustering of SSc cases close to 
airports in south and west London has been reported.9 This 
raises the question whether chronic exposure to exhaust from 
jet engines is also a suspected trigger for SSc onset, although 
this link has not been proven.
Autoimmunity
Evidence of autoimmunity is present in the majority of 
SSc patients at the time of onset of symptoms (such as 
Raynaud’s phenomenon or dysphagia) heralding the onset 
of the disease, suggesting it precedes onset of symptomatic 
SSc. The autoimmune state is characterized by increased 
production of antibodies to not only nuclear antigens but 
also other cellular and noncellular antigens, including 
antibodies to fibrillin-1, platelet-derived growth factor 
(PDGF) receptor, matrix metalloproteinases (MMP) 1 and 
3, endothelial cells, and fibroblasts.10 There is also T cell 
immunity to fibroblasts, muscle cells, types I, III, and IV col-
lagen, laminin, and low molecular weight N-sulfated heparin 
sulfate.11,12 Activated T cells are present in peripheral blood, 
and levels of soluble interleukin (IL)-2 receptor are increased 
in patients with SSc.13–15 Notably, CD4+ CD8+ double positive 
T cells with very high IL-4 expression are found in skin and 
peripheral blood of SSc patients with early active disease.16 
T regulatory cells (T regs) are increased in the peripheral 
blood of patients with SSc but have diminished suppressive 
function, perhaps as a result of increased S1P and/or other 
Table 1 Important differences between lcSSc and dcSSc
Features LcSSc dcSSc
Skin Skin thickening occurs late; limited to distal part of  
upper and lower extremities, face, neck, and upper chest. 
Telangiectasias and calcinosis are common.  
Tendon friction rub not seen.
Skin thickening occurs early; moves up to 
proximal part of extremities and trunk. 
Telangiectasias and calcinosis may occur  
late in disease. 
Tendon friction rub present.
GI esophageal dysmotility is more common than  
small and large intestine involvement.
esophageal dysmotility is frequently seen. 
Small and large intestinal involvement  
is more common.
Pulmonary Pulmonary fibrosis is less frequent and less severe. 
Frequent and severe pulmonary hypertension  
are more common.
Pulmonary fibrosis is more common and severe. 
Pulmonary hypertension is less frequent.
Kidney Renal crisis uncommon Renal crisis is more frequent.
Autoantibody association Anticentromere antibodies are predominant. Anti-Scl-70 antibody is predominant. 
Anti-RNA polymerase antibody is more common.
Abbreviations: dcSSc, diffuse cutaneous systemic sclerosis; GI, gastrointestinal; lcSSc, limited cutaneous systemic sclerosis.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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mediators from mast cells which are known to “disarm” 
T regs.17–20 Vdelta1+/gamma/delta T cells are increased in 
lesional SSc skin, express HLA-DR and very late activation 
antigen alpha4 (CD49d) suggesting that Vdelta1+ T cells 
have homed to fibrotic SSc skin and are expanded.21 The 
activation of T cells in SSc appears to be antigen driven, and 
analysis of T cell receptor repertoire in multiple skin biopsies 
from the same SSc patient indicates they have undergone 
clonal expansion to a widely distributed persistent present 
antigen.22,23 Proliferating activated type I collagen-specific 
CD25+ CD4+ T cells of the memory (CD45 RO+) phenotype 
were isolated from 32% of patients with SSc but from only 
3.6% of healthy or disease controls.12 Further evidence of 
type I collagen-specific immune response in SSc patients was 
shown by using complementary DNA (cDNA) arrays focused 
on immune-related genes. It was observed that patients 
with dcSSc in contrast to healthy volunteers activated more 
immune-related genes in peripheral blood mononuclear cells 
cultured for 24 hours with type I collagen.24 Furthermore, a 
double-blind placebo control trial of oral immune tolerance 
induction with bovine type I collagen in patients with early 
and late stage dcSSc showed an improvement in the modified 
Rodnan skin score in late-stage dcSSc patients (.3–10 years 
duration) who were randomized to the oral collagen group 
versus late-state dcSSc patients receiving placebo.25
Attention has recently focused on the innate immune 
defense system as a facilitator or initiator of autoimmunity. 
Like several other autoimmune diseases, patients with SSc 
have increased expression of interferon (IFN) responsive 
genes, or an “IFN signature”, although it is not clear which 
type of IFN is responsible for the IFN signature in SSc.26 
Polyinosinic/polycytidylic acid (poly(I:C)) (a toll-like 
receptor [TLR] 3 ligand) was shown to induce IFN- and 
transforming growth factor (TGF)-β-responsive genes and 
TLR3 in SSc and normal dermal fibroblasts.27 Furthermore, 
chronic subcutaneous infusion of poly(I:C) in mice produced 
an inflammatory sclerotic skin thickening with increased 
IFN- and TGF-β- response gene upregulation.27
Interestingly, sera or IgG from SSc patients can stimulate 
IFN-α production by peripheral blood mononuclear cells 
(PBMCs).28 Although IFN-α and -β can facilitate B cell 
maturation, it is not clear what role if any this plays in 
SSc pathogenesis and how or if it relates to upregulated 
expression of CD19 and B cell related genes in patients 
with SSc29,30 or other changes in B cells described in 
patients with SSc, including expanded naïve B cells and 
diminished numbers of memory B cells (reviewed in a paper 
by Hasegawa31).
Studies in animal models have shown that induction of 
certain types of immune reactions results in SSc-like disease. 
For example, murine chronic graft versus host disease is a 
useful model to study scleroderma (skin fibrosis). It can be 
created by injecting cells from B10. D2 mice into irradiated 
Balb/C or Balb/C rag2-/- mice, in which there are only minor 
histocompatibility differences.32 This produces scleroderma-
like disease within 4–6 weeks and shows fibrosis/matrix depo-
sition, increase in myofibroblasts, autoantibody production, 
dermal infiltration of immune cells, and upregulation of 
endothelin (ET)-1 in skin and kidney tissue. Immunization 
of New Zealand rabbits with human type V collagen in 
complete Freund’s adjuvant induces a SSc-like skin fibrosis 
with development of antinuclear antibody and anti-Scl70 
antibody.33 In addition, tolerization of C57BL/6 mice with 
intravenous bovine type V collagen inhibited bleomycin-
induced pulmonary fibrosis.34
Vascular changes in SSc
The vascular pathology in SSc is not necessarily an 
inflammatory process and would better be characterized as a 
vasculopathy in the absence of vasculitis. The vasculopathy is 
a systemic process as shown by autopsy studies.35,36 The classic 
autopsy study by D’Angelo et al showed that SSc patients had 
widespread intimal proliferation in the pulmonary, coronary, 
and renal arteries.35 The lesions were not inflammatory, and 
there was intimal hyperplasia involving small and large 
arteries.35 Evidence of vascular injury was reported as early 
as 1925 and shown to be present in multiple vascular beds.36 
Impaired vascular permeability and vascular tone are the 
earliest signs of vascular dysfunction.37 Besides the vascular 
injury, impaired balance of the vasoconstrictor substance ET 
and vasodilator substance nitric oxide play important roles 
in vascular dysfunction. Platelet activation and enhanced 
coagulation with reduced fibrinolysis contribute further to 
the vasculopathy in SSc. Patients with SSc who develop 
pulmonary hypertension and renal crisis show characteristic 
vascular lesions. These lesions show classic concentric intimal 
proliferation, marked luminal obstruction, lymphocyte infiltra-
tion, and relative paucity of plexiform lesions.38–41
The event that initiates vascular injury in patients with SSc 
is currently unknown. Infectious agents, cytotoxic T-cells, 
nitric oxide (NO)-related free radicals, and autoantibodies 
against endothelial cells have been implicated.37 Endothelial 
cell dysfunction, neural abnormalities, and intravascular 
defects could contribute to the impaired vascular flow.42 
The vascular abnormalities of SSc discussed below are 
summarized in Table 2.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Microcirculatory changes involving the arterioles and the 
capillaries are a prominent feature of SSc.43 Abnormality of 
microvasculature such as dropout of capillaries as well as 
abnormal capillary architecture have been documented long 
ago.36 Later studies44,45 showed similar changes which include 
decrease in the number of normal capillaries, swelling of 
endothelial cells, and reduplication of the capillary basement 
membrane. The earliest pathological changes in the vascular 
system can be seen in clinically normal skin.46 Large gaps 
between endothelial cells, vacuolization of endothelial cell 
cytoplasm, and loss of membrane-bound storage vesicles 
are some of the earliest detectable changes in the endothelial 
cells.46–48 Koenig et al showed microvascular changes to 
be sequential in a 20-year follow-up study.49 Capillary 
enlargement is followed by capillary loss and then capillary 
telangiectasias.49 This is followed by morphologic changes 
in the vessels as well as tissue fibrosis.49 Similar changes 
in the capillaries are seen in all involved organs (eg, lungs, 
heart, kidneys, and muscles), demonstrating the widespread 
nature of capillary changes in SSc.50 Intimal proliferation and 
accumulation of proteoglycans in the arterioles and small 
arteries are common as well.51,52
Endothelial cell injury is an early and central event in 
the pathogenesis of SSc vasculopathy.53 The major evidence 
for the presence of the endothelial injury is high serum 
levels of von Willebrand factor,54 ET-1,55 and increased 
level of circulating viable and dead endothelial cells.53,56,57 
However, it is not clear whether it is the initiating event.58 
Following endothelial injury, circulating platelets adhere 
to subendothelial tissue and initiate fibrin deposition and 
intravascular thrombus formation.59 There are conflicting 
reports of endothelial apoptosis. In early lesions there is 
endothelial cell apoptosis or changes of the endothelial cell 
phenotype in the absence of endothelial cell proliferation or 
precursor differentiation.60–62 Immature dendritic cells and 
macrophages may engulf apoptotic cells and subsequently 
present cellular antigens to CD8+ T cells, causing further 
tissue injury.63 These apoptotic endothelial cells can also 
activate the alternate complement pathway and coagulant 
pathway leading to vascular thrombosis.64,65 Viral agents, 
cytotoxic T cells, antibody dependent cellular cytotoxicity, 
anti-endothelial cell antibodies, and ischemia reperfusion 
injury are all suggested mechanisms for endothelial cell 
damage.37 However, Fleming et al60 failed to detect apoptotic 
endothelial cells in their study, although they did demonstrate 
loss of vascular endothelial-cadherin, which regulates 
endothelial barrier function, and found evidence of IFN-α 
signaling. IFN-α signaling suggests endoplasmic reticulum 
stress and the unfolded protein response in these cells.66,67
Pericytes mediate vascular maturation and stabilization 
during angiogenesis68 and have the potential to differentiate 
into vascular smooth muscle cells, fibroblasts, and 
myofibroblasts.69–71 They express several key cytokine 
receptors, including PDGF receptor β and high molecular 
weight melanoma-associated antigen in vascular lesions 
in SSc patients with associated Raynaud’s phenomenon 
and antinuclear antibodies.72 Another marker of angiogenic 
pericytes is regulator of G protein signaling (RGS-5) and 
is highly expressed in SSc vasculature.60 The exact role of 
Table 2 Summary of vascular abnormalities in SSc
I. Microvasculature changes
  A. Dropout of capillaries and altered capillary structure
  B.   Swelling of endothelial cells
  C. Reduplication of capillary basement membrane
  D. Large gaps between endothelial cells
  e.    vacuolization of endothelial cell cytoplasm
  F.  Loss of membrane bound storage vesicles in endothelial cells
  G.   Capillary telangiectasias
  H.   Intimal proliferation and accumulation of proteoglycans in   arterioles 
and arteries
II. Endothelium
  A.   endothelial cell injury reflected in elevated serum von willebrand 
factor, increased serum eT-1 and levels of circulating visible and 
dermal endothelial cells, loss of ve-cadherin, and IFN-α signaling
    1.   Platelets adhere to damaged endothelium initiate fibrin 
deposition and thrombosis
  B. evidence for and against endothelial apoptosis
    1.   Potential mediators of endothelial injury include viral agents, 
cytotoxic T cells, ADCC and isclemia reperfusion injury
  C. Chronic vasoconstrictor signals from endothelial cells
    1. Increased eT-1 and increased eT-1 receptor
    2. Reduced eNOS and reduced NO
III. Pericytes
  A. Upregulation of PDGF receptor β and HMw-MAA
  B.   Proliferate and differentiate into vascular smooth cells, fibroblasts, 
and myofibroblasts contributing to vascular wall thickness
IV. Impaired angiogenesis
  A. Proangiogenic factors are elevated
  B. Antiangiogenic factors are elevated
V. Impaired vasculogenesis
  A.   Circulating endothelial progenitor cells reduced in number or their 
angiogenic potential is reduced
VI. Chronic platelet activation and increased aggregability
  A. Release of vasoactive mediators
    1. Induce vasoconstriction
    2. Promote proliferation of vascular smooth muscle cells
    3. Promote neointima formation
    4. Promote fibrosis
    5. Possibly contribute to hypertension (via release of LPA)
Abbreviations: ADCC, antibody dependent cellular cytotoxicity; eNOS, endothelial 
nitric oxide synthase; eT, endothelin; HMw-MAA, high molecular weight-melanoma 
associated antigen IFN, interferon; LPA, lysophosphatidic acid; NO, nitric oxide;   
PDGF, platelet-derived growth factor; SSc, systemic sclerosis; ve, vascular endothelial.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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RGS-5 is not clear, but current literature suggests that it is a 
negative regulator of vessel maturation.73 Pericytes proliferate 
and contribute to increased vascular wall thickness.74
ET-1 is released from endothelial cells and is a potent 
vasoconstrictor and mitogen for smooth muscle cells and 
fibroblasts.75 Higher levels of ET-1 have been observed in 
patients with scleroderma renal crisis (SRC), lung fibrosis, 
pulmonary hypertension, and Raynaud’s phenomenon.76,77 
Increased ET-1 expression is associated with increased ET-1B 
receptor in the skin and lung tissue of SSc patients.78 ET-1 is 
also a fibrogenic cytokine enhancing fibroblast proliferation 
and synthesis of types I and III collagen, while decreasing 
the expression of MMPs.79
NO is an important vasodilator of vascular smooth 
muscle. The release of NO from vascular endothelium 
sends a powerful signal to the underlying vascular smooth 
muscle wall. In SSc, there is a reduction in endothelial NO 
synthase (eNOS) gene expression and NO release in SSc 
and microvascular endothelial cells derived from lesional 
and nonlesional skin biopsies in the steady state and after 
shear stress.80 This is probably associated with deficient 
endothelium dependent relaxation in SSc.81 Impaired NO 
results in alteration of vascular tone, enhancement of platelet 
aggregation, and increased susceptibility of endothelial 
cells to oxidative injury. NO also limits cytokine-induced 
endothelial cell activation and monocyte adhesion and 
inhibits the endothelial cell release of IL-6 and IL-8, which 
are important inflammatory cytokines.82 Further, NO inhibits 
vascular smooth muscle cell proliferation through elevation 
of cyclic guanosine monophosphate (cGMP) and inhibition 
of mitogenic proteins TGF-β and PDGF. Therefore, impaired 
NO production in SSc may contribute to the pathogenesis 
of arteriolar intimal proliferation and may have a prominent 
role in pathophysiology of the disease.
Angiogenesis is defined as the process where new 
vessels are formed from pre-existing ones. This depends on 
the activation, proliferation, and migration of endothelial 
cells and is driven by angiogenic stimuli that also induce 
proteolytic enzymes, which cleave the extracellular matrix. 
The remarkable loss of capillaries and small vessels in 
patients with SSc suggests a defect in the process of 
angiogenesis. Despite the reduced capillary density, there is 
no significant angiogenic response in SSc. Tissue ischemia 
usually leads to the expression of angiogenic growth factors, 
eg, vascular endothelial growth factor (VEGF), which causes 
vasodilatation, proliferation, and migration of endothelial 
cells, and stabilization of the lumina to form new vessels.83 
Plasma levels of VEGF are elevated in SSc, and this could 
stimulate angiogenesis.83 Levels of other proangiogenic 
factors (eg, PDGF, placental growth factor, and fibroblast 
growth factor [FGF]-2) are also considerably elevated in 
the plasma of SSc patients.84 Expression of VEGF and its 
receptors VEGFR1 and VEGFR2 are increased in skin of SSc 
patients.85–87 In one study,85 upregulation of VEGF was not 
mediated by hypoxia-inducible transcription factor-1 (HIF-1) 
as indicated by only a weak expression of the oxygen-
sensitive α-subunit of HIF-1 in the skin of SSc patients. 
The chronic and uncontrolled overexpression of VEGF is 
thought to be the result of a net effect of cytokines such as 
IL-1 and PDGF. However, in another study, hypoxia was 
associated with increased VGEF level in patients with lcSSc 
and dcSSc as evidenced by elevation of hypoxia associated 
glucose transporter molecule, GLUT-1.87 In addition to 
elevated level of VEGF, other proangiogenic mediators 
such as ET-1, adhesion molecules, and chemokines are 
found in the circulation of SSc patients.32 Elevated levels 
of antiangiogenic factors such as angiostatin, platelet factor 
4 (also called CXCL4), thrombospondin-1, and IL-4 have 
been described.32,88 At the present time it is not clear whether 
dysregulated levels of circulating angiogenic factors or 
antiangiogenic factors contribute to SSc vasculopathy.
Vasculogenesis is defined as formation of new vessels 
from progenitor cells. Bone marrow-derived cells contribute 
to physiological and pathological vascular remodeling. 
Progenitor cells migrate to the sites of vascular injury and 
can differentiate to endothelial cells for vascular repair or can 
differentiate into vascular smooth muscle cells or foam 
cells contributing to neointimal proliferation and vascular 
disease.89,90 The role of vasculogenesis in SSc is not clear, 
and there are conflicting reports regarding the presence and 
role of circulating endothelial progenitor cells in SSc.91 
Increased levels of circulating endothelial progenitor cells 
have been demonstrated, which supports their mobilization 
from bone marrow.92 However, in another study,56 there were 
substantially reduced numbers of bone marrow-derived, 
circulating endothelial precursors compared with healthy 
subjects or patients with rheumatoid arthritis. The lowest 
number of these cells was observed in SSc patients with 
active fingertip ulcers, and this may suggest inadequate 
recruitment of these precursor cells and impaired vascular 
repair mechanisms.56 Atorvastatin can be effective in 
Raynaud’s phenomenon, perhaps by increasing the number 
of circulating endothelial progenitor cells,93 which suggests 
a role of endothelial progenitor cells in vascular dysfunction. 
Apoptosis of endothelial progenitor cells by a circulating 
factor has been implicated as the potential mechanism Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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for the reduced number of circulating precursor cells in 
SSc.94 Mesenchymal stem cells might be another source of 
endothelial progenitor cells. In SSc, the angiogenic potential 
of these cells is reduced.95 This suggests that endothelial 
repair may be affected by unknown SSc disease effects on 
the bone marrow.
Coagulation and fibrinolysis processes are dysregulated 
in SSc. Microvascular thrombosis and enhanced fibrin 
deposition are frequently seen in the vasculature of SSc 
patients, suggesting defective regulation of the coagulation 
and fibrinolytic process. The loss of balance between 
fibrinolysis and coagulation contributes to vessel engulfment 
with fibrin and breakdown of vessel patency.96 In a study 
of 29 SSc patients, the authors demonstrated impairment 
of fibrinolysis and activation of the coagulation pathway.96 
Activation of the coagulation system is described by others, 
and elevated levels of fibrinogen and von Willebrand factor 
have been consistently described in SSc.97–100 Another study 
also found depressed fibrinolysis, expressed as defective t 
plasminogen activator (tPA) antigen release and/or elevated 
tPA inhibitor (PAI) antigen, in support of a heterogeneous 
hypofibrinolytic pattern in SSc.101
Platelet abnormalities are seen in systemic sclerosis and 
play an important role in the pathogenesis of vasculopathy. 
Platelets are in a chronically activated state exhibiting 
enhanced aggregability to various triggers such as 
type I collagen, adenosine diphosphates, 5-hydroxy 
tryptamine (HT),102–104 ET-1, S1P, and LPA (reviewed in 
a paper by Pattanaik and Postlethwaite105). ET-1 induces 
vasoconstriction, as does S1P, by engaging S1P type 2 
and 3 receptors.106 LPA induces platelet aggregation and 
hypertension, and promotes proliferation of vascular smooth 
muscle cells and neointima formation, which can induce 
vasospasm and Raynaud’s phenomenon.107–110
There are reports in the literature that repeatedly 
document ongoing and chronic activation of platelets 
and/or release of their biologically active molecules 
which could contribute to the vascular, immunologic, and 
connective tissue pathology of SSc (reviewed in a paper 
by Postlethwaite and Chiang103). The list of bioactive 
molecules produced or released from platelets is very 
impressive and includes inflammatory mediators (NO, 
serotonin, thromboxane A2, LPA, S1P, prostaglandin (PG) 
D2, PGE2, PGF2, 12-hydroxyeicosatetraeonic acid, β   
thromboglobulin, neutrophil-activating peptide-2, 
platelet factor-4, platelet activating factor, adenosine, 
histamine,  P-selectin,  CD40  ligand,  dinucleoside 
polyphosphates, 2-arachidonyl glyceride, MMP-27), 
chemokines (macrophage inflammatory protein 1α, monocyte 
chemoattractant, protein-3, IL-8, and regulated upon 
activation, normal T-cell expressed and secreted), cytokines 
(IL-1β and granulocyte monocyte-colony stimulating factor 
[GMCSF]), and growth factors (PDGF-A, -B, -C, and -D; 
TGF-β1 and -β2; epidermal growth factor; VEGF-A and 
-C; brain-derived neurotrophic factor; insulin-like growth 
factor-1; basic fibroblasts growth factor; hepatocyte growth 
factor; and connective tissue growth factor [CTGF]) 
(reviewed in a paper by Postlethwaite and Chiang103). Platelets 
from patients with SSc exhibit a signature not observed in 
platelets from normal donors or several other rheumatic 
diseases. This SSc platelet signature is overexpression of 
a specific nonintegrin 65 kDa receptor for type I collagen, 
enhanced expression of phosphitidylinositol (PI)-3 secondary 
to increased nitrotyrosylation, and increased protein kinase 
B (Akt) activity.103,111 There is also indirect evidence that 
the signature may be acquired and induced by cytokines 
produced by T cells and monocytes activated by autoantigen 
such as type I collagen that in turn change the phenotype of 
megakacyocytes.104 Since platelets can chemotax to type I 
collagen and other chemoattractants and leave the vascular 
compartment,112–114 their stores of numerous fibrogenic 
mediators might contribute to chronic tissue fibrosis in SSc 
by release into tissue of TGF-β1 and -β2, PDGF-A, -B, -C, 
and -D, lysophosphatidic acid (LPA), S1P, adenosine, basic 
FGF, CTGF, and insulin-like growth factor (IGF)-1. LPA 
and S1P, which have many biological properties and effects 
on a host of cells that could also facilitate and contribute to 
autoimmunity and fibrosis (reviewed in a paper by Pattanaik 
and Postlethwaite105, discussed below).
Possible insights into SSc vascular  
changes from animal models
Animal studies in mice recapitulate some of the vasculopathy 
of SSc. For example, mice with a conditional deletion of 
Friend leukemia integration (Fli)1 develop systemic vascular 
lesions characterized by capillary dilitation, vascular fragility, 
stenoisis of arterioles, increased vascular permeability, 
micro-aneurysm development, decreased expression of 
platelet/endothelial cell adhesion molecule (PECAM)-1, 
PDGF-B, and S1P1 receptors, and increased endothelial 
cell MMP-9 expression.115 Sgnoc et al61 demonstrated 
endothelial cell apoptosis in the University of California at 
Davis chicken lines 200/206 which spontaneously develop 
an SSc-like disease.
Caveolin-1 is one of three membrane proteins that 
coat caveolae, which are plasma membrane invaginations Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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important in clustering together of receptors that can 
influence signal transmission of the specific receptor 
ligand.116 Caveolin-1 null mice develop pulmonary arterial 
hypertension (PAH) and right and left ventricular enlargement 
and failure.117 However, in contrast to caveolin-1 null mice 
with PAH, in human idopathic PAH, there is an apparent 
increase in caveolin-1 expression in the pulmonary artery 
smooth muscle cells (PASMCs) compared with healthy 
controls and the overexpression of caveolin-1 increases 
capacitative Ca++ entry and DNA synthesis in PASMC.118 
The caveolin-1 null mice also develop pulmonary fibrosis, 
raising questions regarding the etiology of the PAH which is 
yet to be clearly defined. Calveolin-1 is reduced in areas of 
lung fibrosis and in areas of dermal fibrosis in patients with 
SSc, and caveolin-null mice develop dermal fibrosis.116
Fibrosis
Fibrosis is the pathological hallmark of SSc. The fibrotic 
process is most prominent in the skin, lungs, GI tract, heart, 
tendons, and ligaments. The fibrosis is secondary to excessive 
deposition of extracellular-matrix (ECM) components, 
caused by overproduction of collagen and other glycoproteins 
(eg, fibronectin and fibrillin).119,120 There is an alteration of 
the macromolecular arrangement of collagens by cross links 
that are normally seen in bone but not in collagen matrix. 
The cross-links are formed by lysyl hydroxylase 2, the level 
of which is increased in scleroderma.121 Lysyl hydroxylase 2 
is a key enzyme involved in the generation of hydroxylysine 
aldehyde-derived collagen cross-links typically found in bone 
tissue.122 In addition to the increased synthesis of particular 
matrix proteins, there is an altered composition and post-
translational modification of the ECM.123
Patients with stiff skin syndrome (SSS), an autosomal 
dominant congenital form of scleroderma have heterozygous 
missense mutations in the 4th latent TGF-β binding protein-
like domain of the ECM protein fibrillin-1.124 This domain 
harbors the only Arg-Gly-Asp sequence in fibrillin-1 that 
mediates matrix-cell attachments via integrin bridging. 
Mutation in this TGF-β binding domain leads to altered 
cell–matrix interactions. Such altered cell–matrix interaction 
is associated with excessive microfibrillar deposition, 
impaired elastogenesis, and increased TGF-β concentration 
and signaling in the dermis of SSc patients. Gene array 
analyses showed increased expression of fibrillin-1 and 
fibrillin-2 in scleroderma skin and lung fibrosis tissue.125,126 
Fibrillin-2 is involved in matrix deposition, storage, and 
activation of growth factors of the TGF-β super family. 
TGF-β is secreted from cells bound to a member of the latent 
transforming growth factor β binding protein family, which 
in turn interacts with fibrillin-1  and fibrillin-2.127 Increased 
fibrillin-2 expression is associated with latency associated 
protein TGF-β in fibrotic tissue. Fibrillin-2 could serve as 
a structural scaffold to store and release TGF-β and could 
contribute to the activation of fibroblasts during fibrosis 
associated with SSc.128
The most abundant ECM molecule in the fibrotic process 
is type I collagen. Progressive replacement of normal tissue 
architecture by collagen rich extracellular matrix leads to 
organ dysfunction. Excessive connective tissue accumulation 
is due to excessive production by fibroblasts and other 
mesenchymal cells activated by various soluble mediators. 
Impaired ECM degradation and turnover and expansion 
of the pool of mesenchymal cells further contribute to the 
ECM accumulation.129 The exaggerated production of ECM 
macromolecules by the fibroblasts results from the increased 
transcription rates of their corresponding genes.130,131 The 
fibrogenic mechanisms that results in tissue fibrosis in 
SSc are complex and likely not due to a single growth 
factor/cytokine or mediator. This conclusion is reached 
because multiple fibrogenic mediators have been detected 
in SSc fibrotic tissues or in plasma/sera of patients with 
SSc. These include TGF-β1 and -β2, PDGF, IL-4, CTGF, 
IL-13, IL-6, oncostatin M, tryptase, IL-17, IL-5, monocyte 
chemoattractant protein (MCP)-1, S1P, and LPA.10,20,105 
Which mediators drive fibrogenesis in SSc may also depend 
on disease subset type and/or disease duration. For example, 
analysis of gene expression using DNA arrays of biopsies 
from SSc lesional skin showed an inflammatory pattern that 
correlated with T cell infiltration, while a diffuse proliferative 
pattern correlated with increased numbers of proliferative 
cells in the skin.126
IL-4 and TGF-β1 are potent chemoattractants for fibro-
blasts and stimulate fibroblast proliferation and collagen and 
fibronectin synthesis.132–134 CTGF also plays an important role 
in fibrosis.135 Enhanced CTGF expression has been detected 
in SSc lesions. Serum CTGF level is markedly elevated in 
SSc patients compared with normal controls or patients with 
other autoimmune diseases, and correlates closely with the 
degree of skin fibrosis.136 Moreover, CTGF expression is 
elevated in dermal fibroblasts of SSc patients.137
TGF-β receptor internalization and subsequent down-
stream signaling is regulated by caveolin-1, and TGF-β 
receptor is rapidly degraded once it is internalized via 
caveolin-1 lipid rafts.116 Caveolin-1 expression is reduced in 
SSc lesional but not in nonlesional fibroblasts, and treatment 
of SSc fibroblast with a bioactive caveolin-1 fragment Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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reduces collagen synthesis of SSc fibroblasts, inhibits TGF-β 
stimulation of collagen synthesis of normal fibroblasts, and 
reduces lung fibrosis in mice treated with bleomycin.116,138
The degree of perivascular and tissue accumulation of 
T cells, B cells, monocytes, natural killer (NK) cells, and 
mast cells is variable and often present early in the disease. 
The cytokines, growth factors, chemokines, S1P and LPA 
that induce fibrosis that these different cell types release 
would necessarily vary as such cellular infiltrates vary. 
Platelets would be the most constant source of fibrogenic 
mediators in SSc, since they are chronically activated, and 
there is evidence of ongoing aggregation of platelets and 
release of platelet particles in SSc (reviewed in a paper by 
Postlethwaite and Chiang103). Platelets are an especially rich 
source of TGF-β1 and -β2, PDGF-A, -B, -C, and -D, IGF-1, 
S1P, and LPA which promote fibrosis (reviewed in papers by 
Postlethwaite et al10 and Postlethwaite and Chiang103).
The predominant fibroblast type in lesional fibrotic 
SSc skin and tissue is the myofibroblast which expresses 
α smooth muscle actin, contracts matrix, and expresses 
the ED-A splice variant of fibronectin.71 ED-A-containing 
polymerized fibronectin is necessary for the induction of 
the myofibroblastic phenotype by TGF-β1.139 Myofibroblast 
development is profoundly influenced by the mechanical 
microenvironment; in particular, by the organization and 
stiffness of the ECM.140 Myofibroblasts are not increased in 
nonlesional SSc tissue. Myofibroblasts can be induced from: 
1) resident fibroblasts by TGF-β1, TGF-β3, GMCSF, IL-6, 
IL-4, thrombin, bradykinin, and histamine or tryptase from 
mast cells; 2) epithelial cells by oncostatin M and TGF-β1; 
3) endothelial cells by tumor necrosis factor-α; 4) pericytes 
by TGF-β1; and 5) circulating fibrocytes by TGF-β1, IL-4, 
IL-13, PDGF-B, and ET-1.10 Which of these sources is/are 
responsible for the predominant presence of myofibroblasts 
in SSc fibrotic tissue is yet to be determined. Myofibroblasts 
can also be induced by overexpressing in normal human 
dermal fibroblasts, intracellular IL-1 receptor antagonist 
protein (icIL-1ra) which also renders myofibroblasts resistant 
to upregulation of MMP-1 synthesis.141 Intracellular IL-1ra 
is also overexpressed in dermal fibroblasts grown from SSc 
lesional skin.142
LPA-activated chloride channel (IclLPA) activity plays 
an important role in differentiation of fibroblasts to a 
myofibroblast phenotype, is a marker for myofibroblast 
phenotype, and is activated by LPA or S1P as myofibroblasts 
develop from fibroblasts.143 Indeed, fibroblasts grown 
from skin of SSc patients show significantly increased 
IClLPA activity following LPA exposure compared with 
healthy volunteer fibroblasts.143 Thus, these results suggest 
elevated IClLPA activity is a marker of SSc skin fibroblasts. 
A dependency for development of fibrosis on LPA or S1P 
has been demonstrated in several animal models includ-
ing pulmonary fibrosis, liver fibrosis, and renal interstitial 
fibrosis.144–148 S1P has been shown to regulate fibrosis in 
animal models of eye and cardiac fibrosis.149–151
Relation of autoimmunity  
to vascular changes and fibrogenesis 
in SSc
There is no single animal model that recapitulates the natural 
course of human SSc including autoimmune, vascular, and 
fibrotic changes that would allow hypothesis testing and 
intervention to assess the roles and interdependence of these 
three processes. We therefore have to speculate how these 
three basic pathologic processes of SSc are interconnected 
and which of the three processes is most likely to be able to 
modulate the other two in human SSc based on results of a 
large body of data generated in vitro and in vivo.
While Raynaud’s phenomenon is an early and prominent 
feature in most cases of adult SSc seen in the USA, this is 
not the case in some racial/ethnic groups. For example, in 
Nigerians, Raynaud’s is the presenting symptom in only 
14.3%.152 Furthermore, a subset of patients with dcSSc 
present with diffuse skin thickening and no Raynaud’s.153 
This argues against vasculopathy being essential or the 
main driving process in effecting fibrosis in SSc. Based 
on what is known regarding the histology of SSc lesions 
and capabilities of the molecular mediators elaborated by 
immune and inflammatory cells and platelets, it seems most 
plausible that these cells and/or platelets are the most likely 
driving force that effects and/or contributes to fibrosis and 
the vasculopathy (see Figure 1).
We will briefly summarize the evidence for the central 
role of immune/inflammatory cells in the pathogenesis of 
SSc since more detailed descriptions are given in other recent 
reviews.10,105 The autoimmune state in SSc may partially be 
the result of a permissive genetic background and reduced 
suppressive function of T regs.154 It is not apparent why T regs 
in SSc patients have reduced suppressive function, but it is 
now known that mast cells, which are increased in fibrotic 
skin and other tissues early in the disease process can impair 
suppressive function of T regs, and S1P (which is elevated 
in the sera of SSc patients19,143 and produced by mast cells, 
platelets, macrophage/monocytes, and the endothelium) also 
inhibits suppressive function of T regs.18 Furthermore, both 
mast cells and S1P facilitate generation of Th17 T cells, Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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which elaborate IL-17, which in turn promotes inflammation 
and fibrosis.18,19,155 Th17 cells are increased in SSc.154 In SSc, 
the skewing of T cells toward a Th2 cytokine-producing 
phenotype, which is facilitated by S1P and LPA, permits 
production of IL-4 and IL-13 which are fibrogenic.105,156 
Activated B cells in SSc patients acting as antigen-presenting 
cells also preferentially evoke development of Th2 cells.31 The 
heightened autoimmune state plus S1P and LPA elaborated 
by immune inflammatory cells and platelets have properties 
that can effect vascular changes seen in patients with SSc. 
T cell-derived microparticles generated during activation of 
T cells induces endothelial cell dysfunction and vasoconstric-
tion with reduced eNOS expression.157 (see Figure 1).
Treatment options for scleroderma 
vascular disease
In this section, we will focus on the most recent therapies that 
are used to treat Raynaud’s phenomenon, digital ulcers, and 
critical digital ischemia. We will also discuss current drug 
trials that focus on vasculopathy of SSc.
Raynaud’s phenomenon  
and digital ulcers
Raynaud’s phenomenon usually precedes skin fibrosis 
anywhere from months to years and in 50% of patients can result 
in ulceration and critical digital ischemia. The pathogenesis 
of vascular damage includes endothelial cell apoptosis, adhe-
sion molecule upregulation, ischemia-reperfusion reaction, 
platelet activation, activation of inflammatory markers that 
ultimately lead to an imbalance between coagulation and 
fibrinolysis,158,159 with resultant alteration in capillary struc-
ture and progressive decrease in their density with slowing 
of blood flow and increased periods of stasis.160 Secondary 
Raynaud’s phenomenon has pronounced vasospasm, abnor-
malities in blood vessel endothelium, including increased 
abnormalities of calcitonin gene related peptide (CGRP), 
Schematic depiction of interconnection of autoimmunity, vasculopathy
and fibrosis facilitated by LPA and S1P
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Figure 1 Autoimmune state develops in a permissive genetic background and is triggered by unknown factors. It results in generation of autoantibodies, autoreactive T cells, 
and NK cells that can elaborate a host of molecular mediators, cytokines, and growth factors. All these mediators induce vasculopathy and fibrosis (discussed in text). LPA 
and S1P are generated from aggregated platelets, dendritic cells, mast cells, macrophages, and endothelium. S1P may act as facilitators and promote immune/inflammatory 
reactions, cardiac and vascular changes, and fibrosis (discussed in text and reviewed in papers by Postlethwaite et al10 and Postlethwaite11). 
Abbreviations:  AB,  antibody;  ADCC,  antibody  dependent  cellular  cytotoxicity;  AeCA,  anti-endothelial  cell  antibody;  CTGF,  connective  tissue  growth  factor;   
eDA, extra domain A; eT, endothelin; FGF, fibroblast growth factor; IGF, insulin-like growth factor; IL, interleukin; LPA, lysophosphatidic acid; MCP, monocyte chemoattractant 
protein; MMP, matrix metalloproteinase; NK, natural killer; PAH, pulmonary arterial hypertension; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; S1P, 
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ET, and VEGF.161 The approach to treating Raynaud’s 
phenomenon and digital ulcers is focused on targeting 
these structural abnormalities by preventing the root cause 
of vascular damage. Such treatment includes the use of 
vasodilators, NO, PGs, inhibitors of phosphodiesterase, 
angiotensin converting enzyme (ACE) inhibitors, selective 
serotonin reuptake inhibitors, alpha-adrenergic blocking 
agents, ET receptor antagonist, statins, and inhibitors of 
Rho-kinase. Therapeutics targeting coagulation and oxidative 
stress are also being used.
Therapeutics targeting impaired 
vasodilatation
Calcium channel blockers (CCBs)
Blood vessels in patients with Raynaud’s phenomenon have 
an impaired ability to vasodilate. CCBs are the mainstay 
therapy for Raynaud’s phenomenon. Nifedipine, amlodipine, 
and felodipine act on smooth muscle calcium channels. 
Nifedipine is the most widely used and studied CCB used 
in secondary Raynaud’s phenomenon. Both short- and long-
acting nifedipine have been shown to decrease vasospasm 
attacks by 30%.161 Thompson and Pope performed a meta 
analysis of 18 randomized, placebo-controlled, and double 
blind trials looking at the efficacy of CCBs for the treatment 
for primary Raynaud’s phenomenon, concluding that there 
is clinical improvement in the frequency and severity of 
ischemic attacks with a reduction in severity of symptoms 
by 33% during a 1-week period.162 Fifteen percent of patients 
may not tolerate CCBs due to headaches, lower extrem-
ity edema, and worsening of lower esophageal sphincter 
function.163
CGRP
CGRP has been studied in the treatment of Raynaud’s 
phenomenon. CGRP is synthesized and released from 
small, capsaicin-sensitive sensory nerves164 and interacts 
with G-protein-coupled receptors. This interaction results 
in microvascular vasodilatation and increased vascular 
permeability, allowing for blood flow into cold induced 
ischemic tissues.165 CGRP is a potent vasodilator that is 
secreted by nerves that supply blood vessels; neurons 
supplying this peptide are diminished in SSc patients.163,166 
Bunker et al have found that when compared with normal 
digital skin, digital cutaneous microvasculature response to 
cold was diminished in Raynaud’s phenomenon patients at 
20°C and 5°C, suggesting a deficiency of CGRP-containing 
nerves are found in the distal digital skin.167 Treatment 
with intravenous (IV) infusion of CGRP increased blood 
flow in hands and fingers, in addition to increasing hand 
temperature compared with saline control patients. The 
CGRP-treated patients also had improvement in Raynaud’s 
induced ulcers.166
NO
NO is a potent vasodilator that’s synthesized from L-arginine 
by NO synthase (NOS).168 NO causes vasodilatation via 
cGMP modulation.163 The use of NO has been studied in 
SSc-associated Raynaud’s phenomenon. A double-blind 
crossover study using L-arginine 8 g daily for 28 days did not 
show a vascular response in skin blood flow in SSc patients 
with Raynaud’s phenomenon when compared with a control 
group.169 Topical nitrates have been shown to decrease 
the frequency and severity of attacks.170,171 Phase III trials 
using topical nitroglycerin; organogel with nitroglycerin, 
and topical amphiMatrix (National Clinical Trial identifier: 
NCT0026669 and NCT00577304) are currently underway, 
with the outcomes being improvement in Raynaud’s 
phenomenon assessment score, reduction in number of 
events, decrease in duration of events, and decrease in 
symptoms (http://clinicaltrials.gov). Chung et al performed a 
randomized controlled trial using MQX-503 nitroglycerin gel 
on 219 patients with either primary or secondary Raynaud’s 
phenomenon and found that there was a 14% change in 
Raynaud’s phenomenon condition score compared with 
placebo group when gel was applied immediately before 
or within 5 minutes of Raynaud’s phenomenon episode 
when gel was applied up to four times daily. They found no 
statistical difference in the frequency, duration, or subjective 
assessment when compared with a placebo group.172
Prostaglandins
PG use in Raynaud’s phenomenon has been studied 
extensively. Prostacyclin is released by endothelial cells; 
its binding to platelet G protein-coupled receptors activates 
cyclic adenosine monophosphate and inhibits platelet 
activation and myosin light chain kinase causing smooth 
muscle relaxation and vasodilatation by activating protein 
kinase A. Epoprostenol and iloprost are synthetic analogs 
of prostacyclin that have been shown to prevent or lessen 
the effects of Raynaud’s attacks in patients with SSc by 
increasing vascular blood flow and healing ischemic digital 
lesions.173 Wigley et al performed a multicenter, placebo-
controlled, double-blind study evaluating the efficacy of oral 
iloprost 50 µg twice daily for the treatment of Raynaud’s Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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phenomenon due to SSc. In this study they found that oral 
iloprost was no better than placebo in the treatment of 
Raynaud’s phenomenon.174 A Cochrane review by Pope et al 
summarizing seven randomized control trials concluded 
that IV iloprost is effective in decreasing the frequency 
and severity of Raynaud’s phenomenon secondary to SSc 
and preventing or healing digital ulcers, and that oral iloprost 
may have less efficacy than IV iloprost.175 Cyclic IV iloprost 
infusion 2 ng/kg/min for 5 consecutive days for 8 hours/day 
was able to decrease Raynaud’s phenomenon severity score 
and control vasospastic disease.176 Low-dose iloprost therapy 
over 21 days was also found to be as effective as high-dose in 
decreasing digital ulcer frequency and duration of Raynaud’s 
phenomenon.177 It has been suggested that iloprost acts by 
downregulation of endothelial cell adhesion molecules,176 
reducing levels of E-selectin, vascular cell adhesion molecule 
(VCAM)-1, and ET-1,178 and may also act as an antioxidant.179 
Chung and Fiorentino completed a pilot study of treprostinil 
using five patients with digital ulcers due to Raynaud’s 
phenomenon from SSc and found that treprostinil was able 
to prevent the development of new digital ulcers and promote 
healing of baseline ulcers.180 Clinical studies with oral 
treprostinil diethanolamine (DISTOL-1 and DISTOL-PK) 
sustained release formula are currently underway (National 
Clinical Trial identifier NCT00775463 and NCT00848939). 
Side effects of prostaglandins include headache, nausea, 
flushing, and jaw pain.181
Phosphodiesterase (PDe)
PDEs are degradation enzymes that regulate the cGMP 
pathways.182 Cyclic nucleotides are second messengers in 
the NO signaling pathway. NO released from endothelial 
cells activate both membrane-bound and soluble guanylate 
cyclases; enzymes needed to convert guanosin triphosphate 
to cGMP. cGMP inhibits vasculature smooth muscle calcium 
channel release, reducing the concentration of intracellular 
calcium available for binding, and allowing for vascular 
smooth muscle relaxation.182 PDE is also released from 
vascular smooth muscles and acts by degrading cGMP 
and counteracting the downstream effects of NO, thereby 
promoting vascular constriction. PDE inhibitors block PDE 
effect on cGMP allowing for vascular dilatation.
Sildenafil and tadalafil are PDE5 inhibitors that have 
been studied in the treatment of Raynaud’s phenomenon 
symptoms and digital ulcers. Sildenafil is a selective inhibi-
tor of cGMP PDE5, which has been shown to decrease the 
frequency and duration of attacks, lower the mean Raynaud’s 
phenomenon condition score, and increase capillary blood 
flow in patients who are resistant to vasodilatory therapy.182 
Recently, it is has been shown to decrease digital ulcers and 
pain, and improve Raynaud’s phenomenon symptoms.183–185 
Decreases in the mean number of Raynaud’s attacks and 
condition scores were seen after treatment with tadalafil 
10 mg daily for 12 weeks in an open-labeled study looking 
at 20 male patients with SSc. These same authors found that 
ET-1 levels were also reduced.186 A Phase II trial is currently 
underway for PF-00489791, a phosphodiesterase inhibitor, to 
evaluate efficacy of once-daily dosing in reducing vasospasm 
and improving symptoms and signs associated with primary 
and secondary Raynaud’s phenomenon (National Clinical 
Trial identifier: NCT0109492).
Therapeutics targeting impaired 
vasoconstriction
Endothelial cells have a prominent role in regulating 
vascular tone. Disrupting the endothelial lining results in 
vasoconstriction due to an endogenous inhibitor of eNOS; 
reducing the amount of NO produced and resulting in 
vasospasm.163 In addition to having less NO, the endothelium 
also produces ET-1, a potent vasoconstrictor. ET-1 is 
a key mediator of vascular hypertrophy, proliferation, 
inflammation, and fibrosis.91 ET-1 is activated by angiotensin, 
vasopressin, and TGF-β.163 ET-1 has two receptors, (ETA 
and ETB) to which it can bind. ETA receptors are found on 
smooth muscle cells and fibroblasts, whereas ETB are present 
predominantly on endothelial cells but also on smooth muscle 
cells, fibroblasts, and macrophages.160 ETA and ETB receptors 
on smooth muscle cells mediate vasoconstriction by ET-1. 
Vasodilatation by the release of NO and prostacyclin is 
mediated by activation of ETB on endothelial cells. Binding 
to ETB receptors also reduces the levels of ET-1 by inhibition 
of ET converting enzyme-1.160
Endothelin receptor antagonist has been studied in the 
treatment of Raynaud’s phenomenon and digital ulcers 
due to SSc. Bosentan, a dual ET-1 receptor antagonist 
binds specifically to ETA and ETB receptors.160 There have 
been two large trials evaluating the efficacy of bosentan in 
the treatment of Raynaud’s phenomenon-induced digital 
ulcers. RAPIDS-1, a randomized, prospective, placebo 
controlled, double-blind study of 122 patients who had 
received bosentan 125 mg twice daily for a total of 16 
weeks had a 48% reduction in the mean number of new 
ulcers and improvement in hand function. There was also 
a significant reduction (P , 0.0075) in the number of new Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
116
Pattanaik et al
ulcers compared with placebo in patients who had digital 
ulcers at baseline and who were considered high risk for 
developing new ulcers. This study did not show any signifi-
cant difference between treatment groups in the healing of 
existing ulcers.187 In RAPIDS-2, a randomized, double-blind, 
placebo-controlled trial of 188 patients with SSc who had 
at least one active digital ulcer, received bosentan 62.5 mg 
twice daily for 4 weeks followed with 125 mg twice daily 
for 20 weeks revealed that bosentan was able to reduce 
the number of new digital ulcers by 33% compared with 
placebo. There was no difference between healing rates, 
pain, and disability. In both RAPIDS-1 and RAPIDS-2, 
treatment-associated benefit was higher in patients with 
large number of digital ulcers (four or more).188 Along with 
the previous trial (RAPIDS-1), this study showed that use of 
bosentan was associated with peripheral edema and elevated 
transaminases.189 Other smaller studies evaluating bosentan 
for treatment of digital ulcers and healed ulcers also showed 
improvement in ulcers190 and concluded that the drug may 
be a safe long-term alternative for treating recurrence of 
digital and healed ulcers.191 In SSc-associated pulmonary 
hypertension, bosentan was found to decrease serum mark-
ers of endothelin activation: intercellular adhesion molecule 
[ICAM]-1, VCAM-1, P-selectin, and PECAM-1.192 Bosentan 
may act in the same manner in digital ulcers associated with 
SSc Raynaud’s phenomenon. Sitaxentan, a selective ETA 
receptor antagonist has also been shown to treat recalcitrant 
SSc-related digital ulcers, with improvement in pain. It was 
also shown to heal preexistent ulcers, with no development 
of new ulcers.193 Ambrisentan is currently being evaluated in 
lcSSc for improving blood flow to hands and feet (National 
Clinical Trial identifier NCT01072669). Angiotensin 
has both vasoconstrictive and profibrotic properties.163 
Angiotensin II receptor antagonist losartan was studied in 
a 15-week, randomized, parallel-group, controlled trial and 
was found to reduce the severity and frequency of Raynaud’s 
phenomenon. Symptomatic improvement was associated 
with a significant reduction in vascular soluble adhesion 
molecules and procollagen type 1 N-terminal propeptide.194 
A multicenter, randomized, double-blind, placebo-controlled 
trial evaluating ACE inhibitor, quinapril, did not show that it 
had any effect on frequency or severity of Raynaud’s, nor did 
it have an effect on the occurrence of digital ulcers.195
Inhibitors of Rho-kinase and tyrosine 
kinase
Exposure to cold activates vasoconstriction by selectively 
amplifying vascular smooth muscle constriction to 
norepinephrine.163 Alpha-2-adrenoreceptors are increased 
in digital arteries. Prazosin, an α2-adrenergic receptor 
antagonist was studied in two randomized controlled 
crossover trials including 40 patients and was found to be 
modestly effective in the treatment of Raynaud’s phenomenon 
secondary to SSc.196 A selective α2C adrenergic antagonist, 
OPC-28326, was studied in a single-center, double-blind, 
placebo controlled study involving 13 patients who received 
oral drug at either 10 or 40 mg. Patients who received 
40 mg tended to have a shorter period of time to improve 
skin temperature after cold challenge.197 Bailey et al found 
that cooling increased vasoconstriction via activating α2C 
adrenoreceptors and that fasudil, a rho-kinase inhibitor, was 
able to inhibit this cold induced constriction.198 Increase in 
reactive oxygen species has been suggested in the activation 
of Rho/Rho-kinase pathway and the upregulation of α2C-
adrenergic receptors on smooth muscle cells.199 Preliminary 
results for fasudil in the treatment of Raynaud’s phenomenon 
are yet to be published. The primary outcome for this trial 
is time to recover 50% and 70% of fall in baseline skin 
temperature, with secondary outcomes being blood flow 
profile change determined by Laser Doppler 60 minutes 
after cold challenge.
Increased protein tyrosine kinase activity has been linked 
to cold induced smooth muscle contraction. Cooling to 31°C 
resulted in greater arteriole contraction and greater increase 
in tyrosine phosphorylation in patients with Raynaud’s 
phenomenon due to SSc as compared with control.200 
Tyrosine kinase inhibitor was able to reverse the cooling-
induced contraction in patients with primary Raynaud’s 
phenomenon.201 Imatinib mesylate is a tyrosine kinase 
inhibitor that targets three tyrosine kinases: ABL, c-kit, and 
PDGF receptors.202 It competitively binds to the adenosine 
triphosphate-binding pocket of c-ABL and is important in 
downstream signaling of TGF-β and PDGF.203,204 A Phase 
II pilot study of Imatinib in the treatment of refractory SSc 
is currently underway. This efficacy study will evaluate 
the change in digital ulceration at 6 months compared with 
baseline (National Clinical Trial identifier NCT00506831).
Statins
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors 
have been shown to improve endothelial dysfunction, 
decrease blood thrombogenicity, and have anti-inflammatory 
properties and immunomodulatory actions.158 They have been 
found to have a pleotrophic effect on endothelial function205 
thereby retarding vascular injury, and have been studied as 
a possible treatment of Raynaud’s phenomenon and digital Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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ulcers due to Raynaud’s phenomenon. Abou-Raya et al 
studied 84 SSc patients who were blindly randomized 
to receive either 40 mg of atorvastatin or placebo for a 
total of 4 months. At the end of 4 months the patients that 
were treated with atorvastatin had a lower development of 
new digital ulcers compared with the placebo group. These 
patients also had improvement in Raynaud’s phenomenon 
severity and pain score. There was also a significant decrease 
in the biomarkers for endothelial injury from baseline in the 
atorvastatin group, suggesting that statins are able to retard 
vascular injury and improve patient function.158 Recently, 
Kuwana et al conducted a 24-month, open-label trial to 
evaluate long-term effects of statins on vascular symp-
toms in SSc patients. In this study, eight patients received 
atorvastatin 10 mg/day and had improvement in Raynaud’s 
phenomenon with reductions in Raynaud’s condition score 
and reduction in angiogenic factors and vascular endothelial 
activation biomarkers, but there was no improvement in 
circulating endothelial progenitor cells. Improvement was 
seen at both 12 and 24 months.206
Therapeutics targeting reactive 
oxygen species
Oxidative stress is thought to contribute to endothelial 
injury by perioxidation of cell membrane lipids and 
activation of inflammatory cascade.163,186,207 In small studies 
N-acetylcysteine infusion has been shown to improve the 
frequency and severity of Raynaud’s phenomenon and 
digital ulcers.186,207 Long-term and safety studies will need to 
be done in SSc patients with Raynaud’s phenomenon and 
digital ulcers.
Scleroderma renal crisis
SRC almost always is characterized by new onset of 
significant systemic hypertension (.150/85 mm Hg) and 
decreased renal function ($30% reduction in estimated 
glomerular filtration rate [GFR]). Risk factors include early 
dcSSc, presence of anti-RNA polymerase III antibody, 
rapidly progressive skin thickening, presence of tendon 
friction rubs, and recent corticosteroid use in moderate to 
high dose (.15 mg/d).208 Pathogenesis of SRC is not clear. 
Endothelial cell injury leads to the intimal thickening of 
interlobular and arcuate arteries of the renal vascular system. 
Dysregulation of ET-1 receptor expression and fibrosis of the 
glomerular and interstitial compartments may lead to renal 
disease progression.209,210
A number of retrospective and small prospective studies 
have shown that ACE inhibitors are very effective in the 
treatment of SRC.211–214 However, ACE inhibitors should 
not be given prophylactically to SSc patients with normal 
blood pressure, since renal crisis can be masked and develop 
in such patients. Captopril has been the most studied agent, 
and there are very limited data on other ACE inhibitors 
and angiotensin receptor blockers. CCBs or furosemide 
can be added to the ACE inhibitors if blood pressure is not 
still controlled.208 Patients with end-stage renal disease can 
benefit from hemodilaysis or peritoneal dialysis. Steen and 
Medsger212 has noted that improvement in renal function can 
continue up to 18 months following the initiation of dialy-
sis, and some patients can come off dialysis. So, evaluation 
for transplantation does not have to be made immediately 
following the onset of SRC. There is limited experience 
of renal transplantation in SSc. From 1987 through 1996, 
the UNOS registry collected data on 23,838 living and 
67,183 cadaveric renal transplantations, and out of that 260 
transplants had been performed for the renal diagnosis of 
SSc.215 Patient survival with SSc and renal failure is reduced 
compared with transplant recipients with other disorders, 
but outcomes appear to be better than in patients treated 
with dialysis.215–218 Renal transplant should be considered 
in selected cases of SSc renal crisis patients who need renal 
replacement therapy.
Pulmonary arterial hypertension
Pulmonary hypertension is defined as elevation of the 
mean pulmonary artery pressure .25 mm Hg at rest and 
can be seen in both lcSSc and dcSSc. PAH is a subset of PH 
in which the pulmonary capillary wedge pressure (PCWP) 
is #15 mm of Hg, which suggests that elevated pulmonary 
arterial pressure is not due to left sided heart disease. 
PAH is believed to arise from excessive vasoconstrictive 
stimuli such as from thromboxane A2 (from perturbed 
endothelial cells or aggregated/activated platelets) and 
ET-1 and reduced generation of the main vasodilators, 
NO, and prostacyclin synthase which converts arachidonic 
acid to prostacyclin. The 5-year cumulative survival of 
SSc related to PAH is 10% compared with 80% of control 
SSc population without PAH.219 Predictors of PAH include 
presence of anticentromere antibodies, nucleolar pattern 
of ANA, and FVC (forced vital capacity)/DLCO (carbon 
monoxide diffusion lung capacity) ratio of $1.6. PAH can 
be associated with early and late SSc.220 Yearly screening 
echocardiogram with Doppler should be performed, and 
diagnosis is only confirmed by right heart catheterization. 
The following classes of agents have been found to be 
beneficial in PAH.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Prostacyclins
Prostacyclins are important mediators of PAH in SSc. 
Various preparations of prostacyclin analogs are available 
and found to be useful in clinical trials. The first to be 
studied was IV epoprostenol, which is given as continuous 
IV infusion. IV epoprostenol improved exercise capacity, 
functional class, and hemodynamic measures.221 However, 
it is reserved for severe PAH patients refractory to other 
measures because of higher numbers of adverse events and 
the difficulty of administration.222 Subcutaneous treprostinil 
was studied next and has been found to be useful in PAH. 
It improves exercise capacity and hemodynamics and 
reduces clinical events compared with placebo in PAH 
patients.223 Patients with PAH secondary to connective 
tissue disease had similar improvement.224 Inhaled iloprost 
has been studied as well. In a trial involving 203 patients 
with PAH including patients with systemic autoimmune 
disease, it improved hemodynamics and exercise parameters 
compared with placebo.225
endothelin antagonists
Excessive ET-1 production in PAH has been targeted 
by development of ETB and/or ETA receptor antagonists. 
Bosentan is an oral antagonist of ET receptor subtypes 
A and B. It shows improvements of exercise capacity, 
functional class, and hemodynamics in patients with SSc 
and PAH.226,227 Bosentan also improves survival compared 
with historic controls in SSc patients.228,229 Based on 
these studies bosentan has been recommended for the 
treatment of PAH.222 Newer agents such as sitaxsentan 
and ambrisentan block the ETA receptor, and both have 
been shown to be effective in patients with PAH.230–232 
Sitaxsentan has been evaluated in PAH associated with 
connective tissue disease in 42 patients, and the results 
were similar to that of PAH patients without any associated 
connective tissue disease.233 Hepatotoxicity is one of the 
major side effects of endothelin antagonist.234 Peripheral 
edema has also been reported as an adverse event of 
endothelin receptor antagonist.
Selective phosphodiesterase inhibitors
(PDE)-5 inhibitors such as sildenafil and tadalafil inhibit 
degradation of cGMP, thereby providing more cGMP for 
NO-mediated vasodilatation. Sildenafil is approved at a 
dose of 20 mg three times daily for treating PAH. It has 
been shown to improve exercise capacity, hemodynamics, 
and New York Heart Association functional class in patients 
with either idiopathic or connective tissue disease-associated 
PAH.235 Sildenafil has been recommended for use in SSc-
associated PAH if bosentan is not effective or cannot be 
tolerated.222 Recently, similar results were observed with 
another PDE-5 inhibitor, tadalafil at 40 mg/day.232
Imatinib mesylate
Imatinib mesylate is a selective protein tyrosine kinase 
inhibitor against c-abl as well as PDGF receptor. It has 
been shown to be effective against PAH in animal models 
as well as in clinical studies.236–239 It has been suggested 
that imatinib mesylate likely increases the expression 
of Fli1 transcription factor in vascular endothelial cells, 
which is downregulated in SSc through an epigenetic 
mechanism.240
Serotonin inhibitors
Inhibitors of serotonin signaling offers a possible additional 
means of treating PAH. Serotonin has been implicated in 
the pathogenesis of PAH through vasoconstriction and 
stimulation of pulmonary vascular smooth muscle cell 
proliferation.240 Pulmonary microvascular endothelial cells 
derived from patients with primary PAH produce increased 
levels of serotonin in vitro, which can cause hyperplasia of 
pulmonary artery smooth muscle cells.241 5HT transporter 
inhibitors like citalopram and fluoxetine prevent the 
development of PAH in animal models.242 Therefore, 
selective serotonin reuptake inhibitors like citalopram and 
fluoxetine are potential candidates for treatment of PAH in 
patients with SSc.
Conclusion
Vascular complications secondary to PH, renal crisis, 
and digital and general ischemia are important causes 
of morbidity and mortality in SSc. Understanding of the 
vascular abnormalities and the underlying pathogenic 
process is clearly important for providing new insights 
into the treatment of SSc. Recently, several pharmacologic 
agents have improved the management of vascular 
complications of SSc. Extensive fibrosis, autoimmunity, 
and vascular alterations play varying roles in disease 
manifestations of SSc. It is not clear which one of these is 
the initiating event and how each process modulates the 
other two pathologic processes. Endothelial injury is a key 
event in the initiation of the vasculopathy of the SSc, and 
both angiogenesis as well as vasculogenesis are impaired. 
Abnormalities of platelet activation and the coagulation 
system also contribute to the vascular abnormalities. Key 
endothelial products such as ET-1 and NO play important Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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roles in the pathogenesis, and therapeutic products targeting 
them have been found to be useful in the treatment of digital 
ischemia and pulmonary hypertension. The relationship 
between vasculopathy and fibrosis is not clearly understood 
at this point. Endothelial injury and subsequent endothlial-
mesenchymal cell transformation leading to formation of 
active fibroblasts/myofibroblasts and excessive collagen 
accumulation have been proposed as a potential mechanism 
of fibrosis. LPA and S1P have many pleotropic effects that 
lead to changes observed in the vasculature, connective 
tissue, and immune system in patients with SSc, and these 
molecular mediators may be future therapeutic targets for 
treating the disease.
A clear understanding of the relationship between 
autoimmunity, fibrosis, and vasculopathy is important to 
better elucidate the pathogenic mechanism of SSc. New 
animal models that would combine vascular and fibrotic 
aspects of the disease would be helpful in this regard.
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